CMS announces rule to restart risk-adjustment payments

On Tuesday, July 24, CMS released a new rule that will allow risk-adjustment payments, which were halted July 7 and threatened to destabilize health insurance marketplaces by keeping billions of dollars from insurers.

“This rule will restore operation of the risk-adjustment program,” CMS Administrator Seema Verma, MPH, said in a statement. “Issuers that had expressed concerns about having to withdraw from markets or becoming insolvent should be assured by our actions today. Alleviating concerns in the market helps to protect consumer choices.”   

The payments, which do not include public money, transfer funds from insurers who cover healthier populations to those with sicker customers. The program, which amounted to $10.4 billion in payments in 2017, is designed to ensure insurers do not select healthier patients.

America’s Health Insurance Plans, the largest health insurance lobbying group, criticized the initial move to halt payments, while encouraging the Trump administration to quickly address the situation to minimize disruption in the insurance marketplaces.

“We agree that a quick resolution is needed to avoid greater harm to the individual and small group markets,” the group said in a prepared statement. “More than ever, American businesses and families want affordable coverage and care they need and deserve. We encourage the administration to reevaluate its decision and work with all stakeholders to make health care more affordable for all Americans."

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup